Back to Search Start Over

Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study.

Authors :
Cesas A
Urbonas V
Tulyte S
Janciauskiene R
Liutkauskiene S
Grabauskyte I
Gaidamavicius I
Source :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Aug; Vol. 149 (10), pp. 6979-6988. Date of Electronic Publication: 2023 Feb 27.
Publication Year :
2023

Abstract

Purpose: The purpose of our study was to determine whether data on the clinical effectiveness of second-line therapy collected in a real-world setting provide additional valuable information on the optimal sequence of metastatic renal cell carcinoma (mRCC) treatment.<br />Methods: Patients diagnosed with mRCC who were treated with at least one dose of first-line vascular endothelial growth factor (VEGF)-targeted therapy with either sunitinib or pazopanib and with at least one dose of second-line everolimus, axitinib, nivolumab, or cabozantinib were included. The efficacy of different treatment sequences was analyzed based on the time to the second objective disease progression (PFS2) and the time to the first objective disease progression (PFS).<br />Results: Data from 172 subjects were available for analysis. PFS2 was 23.29 months. The 1-year PFS2 rate was 85.3%, and the 3-year PFS2 rate was 25.9%. The 1-year overall survival rate was 97.0%, and the 3-year overall survival rate was 78.6%. Patients with a lower IMDC prognostic risk group had a significantly (p < 0.001) longer PFS2. Patients with metastases in the liver had a shorter PFS2 than patients with metastases in the other sites (p = 0.024). Patients with metastases in the lungs and lymph nodes (p = 0.045) and patients with metastases in the liver and bones (p = 0.030) had lower PFS2 rates than patients with metastases in other sites.<br />Conclusions: Patients with a better IMDC prognosis have a longer PFS2. Metastases in the liver lead to a shorter PFS2 than metastases in other sites. One metastasis site means a longer PFS2 than 3 or more metastasis sites. Nephrectomy performed in an earlier stage of disease or metastatic setting means higher PFS and higher PFS2. No PFS2 difference was found between different treatment sequences of TKI-TKI or TKI-immune therapy.<br /> (© 2023. The Author(s).)

Details

Language :
English
ISSN :
1432-1335
Volume :
149
Issue :
10
Database :
MEDLINE
Journal :
Journal of cancer research and clinical oncology
Publication Type :
Academic Journal
Accession number :
36847839
Full Text :
https://doi.org/10.1007/s00432-023-04645-x